<DOC>
	<DOCNO>NCT02127034</DOCNO>
	<brief_summary>The purpose study evaluate effect steady state solifenacin mirabegron pharmacokinetics co-administered steady state digoxin . This study also evaluate safety tolerability combine steady state administration solifenacin , mirabegron digoxin .</brief_summary>
	<brief_title>Study Evaluate Effect Solifenacin Mirabegron Digoxin Concentrations Blood Healthy Subjects</brief_title>
	<detailed_description>This study comprise two study sequence 2 investigational period sequence . There wash-out period investigational period . Patients admit clinic discharged investigational period .</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subject body mass index range 20.0 30.0 kg/m2 , inclusive . The subject weigh least 50 kg [ screen ] . Female subject must either : Be nonchild bear potential : 1. postmenopausal ( define least 1 year without menses ) prior screen , 2. document surgically sterile Or , childbearing potential , 1 . Agree try become pregnant clinical study 28 day final study drug administration , 2. must negative urine/serum pregnancy test screen day 1 , 3. heterosexually active , agree consistently use 2 form highly effective birth control start screen throughout clinical study period 28 day final study drug administration . Female subject must agree breastfeed start screen throughout clinical study period , 28 day final study drug administration . Female subject must donate ovum start screen throughout clinical study period , 28 day final study drug administration . Male subject female spouse/partners childbearing potential must use highly effective form contraception consist 2 form birth control ( 1 must barrier method ) start screen continue throughout clinical study period 90 day final study drug administration . Male subject must donate sperm start screen throughout clinical study period 90 day final study drug administration Subject agree participate another interventional study participate present clinical study , define signing informed consent form ( ICF ) completion last study visit . Female subject pregnant within 6 month prior screen assessment breast feeding within 3 month prior screen . Subject know suspected hypersensitivity solifenacin succinate , mirabegron , digoxin component formulation use . Subject liver function test ( LFTs ) ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase [ ALP ] , GGT , total bilirubin [ TBL ] ) upper limit normal ( ULN ) . In case assessment may repeat [ day 1 ] . Subject clinically significant history allergic condition . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior day 1 . Subject clinically significant abnormality follow Investigator 's review physical examination , ECG ( e.g. , level sinus node disease atrioventricular defect ) protocol define clinical laboratory test ( e.g. , electrolyte abnormality hypokalemia ) screen day 1 . Subject history evidence clinically significant cardiovascular , gastrointestinal , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy , judge medical Investigator . Subject mean heart rate ( HR ) &lt; 50 &gt; 90 beat per minute ( bpm ) ; mean systolic BP &gt; 140 mmHg ; mean diastolic BP &gt; 90 mmHg day1 ( vital sign measurement take triplicate subject rest supine position 5 min ; pulse measure automatically ) . Subject mean QTc ( F ) interval &gt; 430 m ( male ) &gt; 450 m ( female ) day1 . If mean QTc ( F ) exceed limit , 1 additional triplicate ECG take . If triplicate also give abnormal result subject exclude . Subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history Long QT Syndrome . Subject clinically significant history risk urinary retention , severe gastrointestinal condition ( include toxic megacolon ) , myasthenia gravis narrowangle glaucoma . Subject use prescribe nonprescribed drug ( include vitamin , hormone replacement therapy natural herbal remedy [ e.g. , St. John 's Wort ] ) 2 week prior study drug administration , except occasional use paracetamol ( 2 g/day ) . Subject history smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit . Subject history drink 21 unit ( 14 unit female ) alcohol per week ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit . Subject consumes grapefruit juice ( 3 x 200 mL ) marmalade ( 3 time ) star fruit , Seville oranges Seville orange juice contain product week prior admission clinical unit end study visit ( ESV ) , report subject . Subject use drug abuse within 3 month prior admission clinical unit . Subject regularly us inducer metabolism ( e.g. , barbiturate , rifampin ) 3 month prior admission clinical unit . Subject significant blood loss , donate 1 unit ( 500 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission day 1 . Subject positive serology test hepatitis B surface antigen ( HBsAg ) , hepatitis B core ( HBc ) antibody , hepatitis A virus ( HAV ) antibody ( Immunoglobulin M [ IgM ] ) , hepatitis C virus ( HCV ) antibodies human immunodeficiency virus ( HIV ) 1+2 antibody . Subject participate clinical study treat investigational drug within 28 day prior screen . Subject vulnerable subject ( e.g. , subject kept detention ) . Subject employee Astellas Group Contract Research Organization ( CRO ) involve clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Digoxin</keyword>
</DOC>